Extractables and Leachables Testing Services Market, 2018-2028
LONDON, Nov. 6, 2018 /PRNewswire/ -- INTRODUCTION
Harmful chemicals / contaminants from primary packaging have often been shown to migrate into pharmaceutical products, threatening the safety of several patients who use these products. For instance, in 2010, McNeil Consumer Healthcare was compelled to recall more than 500 lots of Tylenol, Motrin, Benadryl and Zyrtec upon being made aware of the presence of an antifungal chemical, called 2, 4, 6-tribromoanisole (which is used to chemically treat shipping pallets), in the aforementioned product formulations. In this particular case, the chemical, which is a potential carcinogen, had leached from the pallet, through the outer packaging into the drug containers. It is worth highlighting that this incident caused the manufacturer to suffer a loss of approximately USD 900 million. In fact, in 2014, data by the FDA demonstrated that in the previous two years, there have been over 2,000 drug and device recalls. In the year 2014 alone, FDA has recalled over 800 drugs. In addition, in 2015, Allergan voluntarily recalled certain batches of its eye ointment due to contamination reported by customers.
Download the full report: https://www.reportbuyer.com/product/5608403
Considering the aforementioned cases, it can be inferred that, during drug product manufacturing and fill / finish, it is important to consider not only the impurity profiles of the drugs, but also identify potential sources of contamination in the containers / packaging material used. Extractables is the term used to refer to compounds that are extracted from the material used to fabricate closed container systems, in the presence of a particular solvent. On the other hand, leachables are substances that passively migrate into drug formulations from the container closure system used, upon direct contact with the product. Further, due to high variability in the type of impurities (organic (volatile, non-volatile or semi- volatile compounds) or inorganic (metals or salts) elements) that are usually extracted / leached out of various manufacturing components and container closures, it is not possible to identify, characterize and quantify all extractables, using a single analytical technique. Nowadays, a variety of testing solutions / assays are available to assess the risk associated with the migration of mobile chemical species from either the components used during manufacturing, or storage containers. Moreover, regulatory bodies have implemented stringent guidelines, making it mandatory for drug developers and packaging service providers to closely monitor the levels of extractables and leachables in pharmaceutical products, drug delivery systems and biomedical devices. Presently, a number of companies offer services for extractables and leachables testing, and such offerings have grown to become an important segment of the overall pharmaceutical industry.
SCOPE OF THE REPORT
The 'Extractables and Leachables Testing Services Market, 2018-2028' report provides an extensive study on the current market landscape and future outlook of the players offering such services. The study features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst various elements, the report includes:
• A detailed assessment of the current market landscape of companies offering extractables and leachables testing services, including information on their respective geographical location, company size, types of pharmaceutical products tested (parenteral, ophthalmic, topical, nasal and others), types of container closures and devices tested (container closure components, single use systems, medical devices and combination products, electronic nicotine delivery systems and others), types of techniques used (spectroscopic techniques, chromatographic techniques and others) and different regulatory guidelines that they comply with.
• A competitiveness analysis of contemporary service providers, presented in the form of a 2X2 matrix, highlighting the most important companies within North America, Europe and Asia Pacific, based on the number of products tested, number of techniques used, extent of regulatory compliance and the company's experience.
• Comprehensive profiles of service providers, featuring brief overview of the company, details on its extractables and leachables testing services portfolio, information on the location of their headquarters, year of establishment, recent developments and a detailed future outlook. In addition, each profile features a peer group-based benchmark comparison matrix, wherein the companies that have been profiled were compared on the basis of several different parameters, such as the number of products tested, number of techniques used, extent of regulatory compliance and the company's experience.
• A detailed analysis of the acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired from 2013-2018, along with the geographical distribution of this activity. The analysis features an ownership change matrix and presents a detailed financial evaluation of the aforementioned deals (in terms of company revenues and deal multiples).
• An elaborate discussion of the various guidelines laid down by major regulatory bodies across different countries and the risk-based approach to extractables and leachables testing. The section also highlights the various regulatory considerations for specific products, such as single use systems, biopharmaceuticals, parenteral and ophthalmic drug products (PODPs) and electronic nicotine delivery systems.
• An analysis on packaging trends for drugs approved in the last five years (beginning 2014). In this section, we have analyzed the various container closure systems used based on parameters such as year of approval of the drug, type of molecule, dosage forms and the packaging material(s) used.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on a proprietary forecast model, we have provided insights on the likely evolution of the market in different regions, including North America, Europe, Asia-Pacific and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the type of service provider companies (small-sized, mid-sized and large companies) and types of products being tested (pharmaceutical products, container closure systems, medical devices and combination products). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:
• Cheryl Johnson (Commercial Development Manager of Biotechnology, Alcami)
• Mike Ludlow (Technical Study Manager Drug Development Services, LGC)
• Mourad Rahi (Director of Analytical Services, American Preclinical Services)
• Roger Pearson (President of Analytical Services, Aspen Research)
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts' views
CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the extractables and leachables market and its likely evolution in the mid-long term.
Chapter 3 provides a general introduction to extractables and leachables, highlighting the significance of testing for such chemical contaminants along with details on the different stages of the investigation process. In addition, the chapter describes the various techniques used in the detection of different organic and inorganic impurities. It also features a discussion on the regulatory guidelines for extractables and leachables testing and the challenges faced by service providers engaged in this domain.
Chapter 4 includes a comprehensive market landscape analysis of companies offering services for extractables and leachables testing. The chapter presents detailed analyses based on the geographical location, company size, types of pharmaceutical products tested (parenteral, ophthalmic, topical, nasal, and others), types of container closures and devices tested (container closure components, single use systems, medical devices, combination products, electronic nicotine delivery systems, and others) and types of techniques used (spectroscopic techniques, chromatographic techniques, and others) ) and different regulatory guidelines that they adhere to. In addition, it presents a bubble analysis, summarizing the regulatory initiatives of key players in this domain.
Chapter 5 provides a comparative landscape of contemporary service providers based on various parameters, such as number of products tested, number of techniques used, extent of regulatory compliance and the experience of the company. Based on the aforementioned analysis, the chapter highlights the most active players within North America, Europe and Asia-Pacific, presented in the form of 2X2 matrix.
Chapter 6 presents detailed profiles of some of the active players engaged in providing extractables and leachables testing services to biopharmaceutical companies across different geographies. Each profile includes a brief overview of the company, details on its extractables and leachables testing services portfolio, year of establishment, recent developments, and a comprehensive future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the profiled players.
Chapter 7 presents a detailed analysis of the acquisitions that have taken place within this industry, providing information on both the acquiring and the acquired companies (location of headquarters and ownership (public / private)), along with the year of acquisition, acquisition cost (if available), and the financial status of the acquired company at the time of the acquisition. It also features a detailed ownership change matrix depicting the distribution of acquisitions across private firms and public firms. It also includes an analysis of the financials of these deals (revenues of the acquired firms at the time of acquisition and their respective deal multiples).
Chapter 8 features a detailed discussion on the regulatory guidelines issued by different authorities, such as the EMA, Health Canada and US FDA. In addition, the chapter presents details on the risk-based approach to extractables and leachables testing, toxicological assessments, and regulatory considerations for specific products.
Chapter 9 presents a comprehensive market forecast analysis, highlighting the future potential of the extractables and leachables testing services domain till the year 2028. It also features the likely distribution of the upcoming opportunity across [A] key geographies, (North America, Europe, Asia Pacific and the rest of the world), [B] size of the service provider (small-sized, mid-sized and large companies), and [C] types of products tested (pharmaceutical products, container closure systems, medical devices and combination products).
Chapter 10 features packaging trends for drugs approved in the last five years (beginning 2014). In this section, we have analyzed the various container closure systems used based on parameters such as year of approval of the drug, type of molecule, dosage forms and the packaging material(s) used.
Chapter 11 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of person name) Cheryl Johnson (Commercial Development Manager of Biotechnology, Alcami), Mike Ludlow (Technical Study Manager Drug Development Services, LGC), Mourad Rahi (Director of Analytical Services, American Preclinical Services) and Roger Pearson (President of Analytical Services, Aspen Research).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.
EXAMPLE HIGHLIGHTS
1. During our research, we identified over 100 players offering a wide range of extractables and leachables testing services for a variety of pharmaceutical products (such as parenteral formulations, ophthalmic formulations, inhalation drugs, oral solutions and topical or transdermal products), medical devices (such as single use systems, combination products, implants and electronic nicotine delivery systems) and container closure systems. Some players claim to offer services for majority of the products listed above. Examples of such players include (in alphabetical order) American Preclinical Services, Bibra Toxicology Advice & Consulting, Sterigenics, Pine Lake Laboratories, Smithers Rapra and Vimta. It is also worth mentioning that the market is highly fragmented, featuring the presence of several large companies (33%), mid-sized companies (26%) and small-sized companies (41%).
2. Approximately 50% of the companies offering extractables and leachables testing services are based in North America, primarily in the US. Examples of key players in this region include (in alphabetical order, no specific selection criteria) Aspen, Alcami, EKG Labs, Merck, NSF and VR Analytical. On the other hand, close to 35% of such companies are based in Europe, while the remaining are located in the Asia Pacific and the rest of the world. Examples of service providers based in the Europe and Asia Pacific include (in alphabetical order, no specific selection criteria) Eurofins, First Source Laboratories, GVK Biosciences, Intertek, LGC, Reading Scientific Services, Sartorius, Schott and WuXi AppTec.
3. Companies engaged in this domain use a diverse range of analytical techniques, such as GC-MS, LC-MS, ICP, HPLC, FT-IR and NMR, for the detection of a wide range of potential impurities in pharmaceutical products and / or primary packaging. Over 30% of the companies we identified offer the necessary expertise for a relatively broader suite of analytical techniques. Examples include (in alphabetical order, no specific selection criteria) ARDL, Avecia Pharma, BioScreen Testing Services, Mérieux NutriSciences Italia, Quantex Laboratories, Recipharm, and VITAS Analytical Services.
4. Nearly 30 acquisitions have taken place among stakeholders in this domain during the period 2013-2018. An evaluation of the financial terms of these deals revealed that over 40% of the companies (for which the acquisition cost was revealed) were acquired for relatively higher deal multiples as compared to their stated revenues at the time of their acquisition. Examples of companies acquired after 2016 include (in alphabetical order) Concept Life Sciences, Crawford Scientific, EAG Laboratories, Halo Pharmaceutical, and Toxikon Europe.
5. Majority of the service providers claim to operate in compliance to guidelines issued by the FDA. In addition, we were able to confirm that nearly 50 service providers have based their working protocols in accordance to US Pharmacopeia guidelines. Similar guidelines (specific to analytical testing) have also been laid down by other regulatory authorities across the globe; examples include ICH, EMEA, MHRA, PQRI, BPOG and ISO.
6. We expect the extractables and leachables testing services market to grow at an annualized rate of ~10% in the period between 2018 and 2028. It is important to mention that small and mid-sized service providers with expertise in analytical testing services, including extractables and leachables testing, are estimated to currently capture nearly 30% of the overall market share; by 2028, this share is likely to grow up to 40%.
7. In terms of the geographical activity, North America (primarily US) and Europe currently capture the largest share (close to 60%) in the extractables and leachables services market. This is followed by Asia Pacific and rest of the world, which currently capture around 40% of the overall market share. This trend is not likely to change significantly in the future.
Download the full report: https://www.reportbuyer.com/product/5608403
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article